StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-12 | $0.66 | $0.66 | +0.29% | 0.1M |
| 05-13 | $0.66 | $0.65 | -1.23% | 0.0M |
| 05-14 | $0.65 | $0.63 | -3.66% | 0.0M |
| 05-15 | $0.62 | $0.61 | -2.17% | 0.0M |
| 05-18 | $0.63 | $0.60 | -5.10% | 0.1M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
| Metric | Annual 2019 2019-12-31 | Annual 2019 2019-09-30 | Annual 2019 2019-06-30 | Annual 2019 2019-03-31 |
|---|---|---|---|---|
Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
Operating Income | $-45.88M | $-29.96M | $-19.97M | $-9.75M |
Net Income | $-46.39M | $-30.18M | $-20.01M | $-9.61M |
EPS (Diluted) | Not available | Not available | Not available | Not available |
Total Assets | $73.44M | $83.83M | $92.63M | $50.48M |
Total Liabilities | $21.79M | $21.39M | $21.18M | $22.01M |
Cash & Equivalents | $61.41M | $72.79M | $83.13M | $36.10M |
Free Cash Flow OCF − CapEx | $-35.93M | $-25.55M | $-16.22M | $-6.78M |
Shares Outstanding | 39.40M | 39.58M | 39.45M | 27.56M |
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.
No sell-side coverage available for MBIO.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Fundamentals not available for MBIO.
No fundamental metrics available yet for this ticker — common for ETFs, foreign issuers without US listing depth, very recent IPOs, or thinly-traded OTC names. The Financials tab pulls from SEC EDGAR directly and may still have data.
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.